Maker of Wegovy, Ozempic showers money on US obesity doctors

Novo Nordisk, a Danish pharmaceutical company renowned for its diabetes medicines, is now positioning itself as the world's leading weight-loss company. The company aims to target the global population of 764 million people with obesity, with the United States being its most lucrative market. In the U.S., where over two-thirds of adults are either overweight or obese, Novo charges customers $1,300 per month for the weekly injection of Wegovy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/s8YSovz
via IFTTT